Agile Therapeutics Inc. Stock
Your prediction
Agile Therapeutics Inc. Stock
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -5.660% | -35.714% | -23.680% | -74.673% | -74.309% | -81.771% | -97.186% |
| Evolus Inc | -0.740% | 23.433% | 12.001% | 29.160% | 18.495% | -25.770% | -32.021% |
| Rhythm Pharmaceuticals | -1.010% | 10.615% | 4.211% | 28.571% | 5.882% | 341.964% | 768.421% |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat